Skip Nav Destination
Close Modal
Update search
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
Filter
All
- All
- Title
- Author
- Author Affiliations
- Full Text
- Abstract
- Keyword
- DOI
- ISBN
- EISBN
- ISSN
- EISSN
- Issue
- Volume
- References
NARROW
Format
Subjects
Journal
Article Type
Issue Section
Date
Availability
1-20 of 40
Keywords: Sorafenib
Close
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
1
Sort by
Journal Articles
Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Journal:
Liver Cancer
Liver Cancer (2024) 13 (5): 548–560.
Published Online: 21 February 2024
...Richard S. Finn; Masatoshi Kudo; Gisoo Barnes; Tim Meyer; Frederic Boisserie; Ramil Abdrashitov; Yaxi Chen; Songzi Li; Andrew X. Zhu; Shukui Qin; Arndt Vogel Introduction: RATIONALE-301 (NCT03412773) was a global, phase 3 study comparing the efficacy and safety of tislelizumab with sorafenib...
Journal Articles
Ghassan K. Abou-Alfa, Peter R. Galle, Yee Chao, Joseph Erinjeri, Jeong Heo, Mitesh J. Borad, Angelo Luca, James Burke, Adina Pelusio, Delphine Agathon, Monika Lusky, Caroline Breitbach, Shukui Qin, Edward Gane
Journal:
Liver Cancer
Liver Cancer (2024) 13 (3): 256–272.
Published Online: 30 September 2023
...), an oncolytic and immunotherapeutic vaccinia virus, given to patients with hepatocellular carcinoma (HCC), is associated with both local and distant tumor responses. We hypothesized subsequent treatment with sorafenib could demonstrate superior efficacy. Methods: This random phase III open-label study evaluated...
Journal Articles
Masatoshi Kudo, Kazuomi Ueshima, Masafumi Ikeda, Takuji Torimura, Nobukazu Tanabe, Hiroshi Aikata, Namiki Izumi, Takahiro Yamasaki, Shunsuke Nojiri, Keisuke Hino, Hidetaka Tsumura, Teiji Kuzuya, Norio Isoda, Michihisa Moriguchi, Hajime Aino, Akio Ido, Naoto Kawabe, Kazuhiko Nakao, Yoshiyuki Wada, Sadahisa Ogasawara, Kenichi Yoshimura, Takuji Okusaka, Junji Furuse, Norihiro Kokudo, Kiwamu Okita, Philip James Johnson, Yasuaki Arai, on behalf of the TACTICS Study Group
Journal:
Liver Cancer
Liver Cancer (2022) 11 (4): 354–367.
Published Online: 10 February 2022
...-targeted agents versus TACE alone revealed no clinical benefits in progression-free survival (PFS) or overall survival (OS). Here, we report the final OS analysis from the TACTICS trial, which previously demonstrated significant improvement in PFS with TACE plus sorafenib in patients with unresectable...
Journal Articles
Kazufumi Kobayashi, Sadahisa Ogasawara, Aya Takahashi, Yuya Seko, Hidemi Unozawa, Rui Sato, Shunji Watanabe, Michihisa Moriguchi, Naoki Morimoto, Satoshi Tsuchiya, Kenji Iwai, Masanori Inoue, Keita Ogawa, Takamasa Ishino, Terunao Iwanaga, Takafumi Sakuma, Naoto Fujita, Hiroaki Kanzaki, Keisuke Koroki, Masato Nakamura, Naoya Kanogawa, Soichiro Kiyono, Takayuki Kondo, Tomoko Saito, Ryo Nakagawa, Eiichiro Suzuki, Yoshihiko Ooka, Shingo Nakamoto, Akinobu Tawada, Tetsuhiro Chiba, Makoto Arai, Tatsuo Kanda, Hitoshi Maruyama, Kengo Nagashima, Jun Kato, Norio Isoda, Takeshi Aramaki, Yoshito Itoh, Naoya Kato
Journal:
Liver Cancer
Liver Cancer (2022) 11 (1): 48–60.
Published Online: 06 December 2021
... Sorafenib Regorafenib Lenvatinib Ramucirumab Hepatocellular carcinoma (HCC) is ranked as the sixth most common neoplasm and the third leading cause of cancer-related death, with 841,080 cases diagnosed and 781,631 deaths in 2018 [1-3]. Its incidence is expected to increase and remains one...
Journal Articles
Robin K. Kelley, Nancy M. Joseph, Halla S. Nimeiri, Jimmy Hwang, Laura M. Kulik, Zoe Ngo, Spencer C. Behr, Courtney Onodera, Karen Zhang, Andrea G. Bocobo, Al B. Benson, Alan P. Venook, John D. Gordan
Journal:
Liver Cancer
Liver Cancer (2021) 10 (6): 561–571.
Published Online: 06 September 2021
... of hepatocellular carcinoma (HCC) tumors and is associated with poor prognosis. In preclinical models of HCC, the combination of mTOR pathway inhibition with the multikinase inhibitor sorafenib improves treatment efficacy. A prior phase I study of the allosteric mTOR inhibitor temsirolimus combined with sorafenib...
Journal Articles
Arndt Vogel, Catherine Frenette, Max Sung, Bruno Daniele, Ari Baron, Stephen L. Chan, Jean Frédéric Blanc, Toshiyuki Tamai, Min Ren, Howard J. Lim, Daniel H. Palmer, Yuko Takami, Masatoshi Kudo
Journal:
Liver Cancer
Liver Cancer (2021) 10 (5): 510–521.
Published Online: 15 July 2021
... carcinoma (uHCC) impacts survival and could impact efficacy outcomes and safety profiles of treatments. This post hoc analysis of the phase 3 REFLECT study examined the efficacy and safety outcomes for lenvatinib and for sorafenib in patients with uHCC, assessed by Child-Pugh score (CPS) and albumin...
Journal Articles
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Journal:
Liver Cancer
Liver Cancer (2021) 10 (4): 370–379.
Published Online: 15 June 2021
...; Vittorina Zagonel; Giovanni Brandi; Tiziana Pressiani; Piera Federico; Caterina Vivaldi; Irene Bergna; Claudia Campani; Fabio Piscaglia Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib...
Journal Articles
Changhoon Yoo, Jwa Hoon Kim, Min-Hee Ryu, Sook Ryun Park, Danbi Lee, Kang Mo Kim, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Joycelyn Lee, David Tai, Stephen Lam Chan, Baek-Yeol Ryoo
Journal:
Liver Cancer
Liver Cancer (2021) 10 (2): 107–114.
Published Online: 03 March 2021
... patients were classified as Child-Pugh A and Barcelona-Clinic Liver Cancer stage C. Multikinase inhibitors (MKIs), including sorafenib ( n = 29), lenvatinib ( n = 19), and cabozantinib ( n = 1), were used as second-line therapy for all patients. The objective response rate and disease control rate were 6.1...
Journal Articles
Journal:
Liver Cancer
Liver Cancer (2021) 10 (1): 1–9.
Published Online: 28 January 2021
..., instructions or products referred to in the content or advertisements. Molecular targeted therapy Sorafenib Regorafenib Lenvatinib Sequential therapy Sorafenib was approved in Europe and the United States in 2007 [ 1, 2 ] and in Japan in 2009. Since its approval, molecular targeted...
Journal Articles
Kerstin Schütte, Regina Schinner, Mathias P. Fabritius, Melina Möller, Christiane Kuhl, Roberto Iezzi, Osman Öcal, Maciej Pech, Bora Peynircioglu, Max Seidensticker, Rohini Sharma, Daniel Palmer, Jean-Pierre Bronowicki, Peter Reimer, Peter Malfertheiner, Jens Ricke
Journal:
Liver Cancer
Liver Cancer (2020) 9 (6): 771–786.
Published Online: 11 November 2020
... of survival. Objective: To evaluate the impact of extrahepatic metastases on survival in patients with HCC treated with sorafenib or with a combination of sorafenib and selective internal radiation treatment (SIRT). Methods: SORAMIC is a randomized, controlled trial comprising diagnostic, local ablation...
Journal Articles
Kazuomi Ueshima, Sadahisa Ogasawara, Masafumi Ikeda, Yutaka Yasui, Takeshi Terashima, Tatsuya Yamashita, Shuntaro Obi, Shinpei Sato, Hiroshi Aikata, Takumi Ohmura, Hidekatsu Kuroda, Takamasa Ohki, Kengo Nagashima, Yoshihiko Ooka, Masahiro Takita, Masayuki Kurosaki, Kazuaki Chayama, Shuichi Kaneko, Namiki Izumi, Naoya Kato, Masatoshi Kudo, Masao Omata
Journal:
Liver Cancer
Liver Cancer (2020) 9 (5): 583–595.
Published Online: 24 July 2020
...; Namiki Izumi; Naoya Kato; Masatoshi Kudo; Masao Omata Background: Prior to the approval of sorafenib, hepatic arterial infusion chemotherapy (HAIC) was offered to patients with advanced hepatocellular carcinoma (HCC) in East Asia, particularly Japan. According to the Japanese guidelines, HAIC...
Journal Articles
Haijing Deng, Anna Kan, Ning Lyu, Luwen Mu, Yi Han, Longzhong Liu, Yanyu Zhang, Youfa Duan, Shuangye Liao, Shaolong Li, Qiankun Xie, Tianxiao Gao, Yanrong Li, Zhenfeng Zhang, Ming Zhao
Journal:
Liver Cancer
Liver Cancer (2020) 9 (3): 338–357.
Published Online: 25 February 2020
... or sorafenib treatment, respectively. T cell function was analyzed by flow cytometry and lactate dehydrogenase assay. In vivo experiments were conducted in murine H22 and Hepa 1–6 competent models of HCC. Local immune infiltration in the tumor microenvironment (TME) was assessed using multicolor flow cytometry...
Journal Articles
Zhexuan Wang, Enxin Wang, Wei Bai, Dongdong Xia, Rong Ding, Jiaping Li, Qiuhe Wang, Lei Liu, Junhui Sun, Wei Mu, Hui Zhao, Xingnan Pan, Guoliang Shao, Xiaoli Zhu, Guowen Yin, Haibin Shi, Jianbing Wu, Zhengyu Lin, Shufa Yang, Jueshi Liu, Wenhui Wang, Xu Zhu, Yong Lv, Jing Li, Hui Chen, Wenjun Wang, Kai Li, Xulong Yuan, Tanlei Yu, Jie Yuan, Xiaomei Li, Jing Niu, Zhanxin Yin, Jielai Xia, Daiming Fan, Guohong Han
Journal:
Liver Cancer
Liver Cancer (2020) 9 (3): 308–325.
Published Online: 19 February 2020
...; Kai Li; Xulong Yuan; Tanlei Yu; Jie Yuan; Xiaomei Li; Jing Niu; Zhanxin Yin; Jielai Xia; Daiming Fan; Guohong Han Introduction: The benefits of combining transarterial chemoembolization (TACE) and sorafenib (TACE-S) over TACE alone for treatment of unresectable hepatocellular carcinoma (HCC) remain...
Journal Articles
Chang Min Kim, Shin Hwang, Bhumsuk Keam, Yun Suk Yu, Ji Hoon Kim, Dong-Sik Kim, Si Hyun Bae, Gun-Do Kim, Jong Kyu Lee, Yong Bae Seo, Soon Woo Nam, Koo Jeong Kang, Luigi Buonaguro, Jin Young Park, Yun Soo Kim, Hee Jung Wang
Journal:
Liver Cancer
Liver Cancer (2020) 9 (2): 182–192.
Published Online: 18 February 2020
...) with molecular targeted drugs (e.g., sorafenib) results in a poor overall tumor response when tumor subtyping is absent. Patient stratification based on actionable gene expression is a method that can potentially improve the effectiveness of these drugs. Here we aimed to identify the clinical application...
Journal Articles
Angel Alsina, Masatoshi Kudo, Arndt Vogel, Ann-Lii Cheng, Won Young Tak, Baek-Yeol Ryoo, Thomas R. Jeffry Evans, Carlos López López, Bruno Daniele, Soamnauth Misir, Min Ren, Namiki Izumi, Shukui Qin, Richard S. Finn
Journal:
Liver Cancer
Liver Cancer (2020) 9 (1): 93–104.
Published Online: 16 December 2019
... and overall survival (OS) is important for maximizing OS for patients with hepatocellular carcinoma. Objective: In this post hoc analysis, we investigated OS in lenvatinib- and sorafenib-treated patients from the REFLECT study, who then received subsequent anticancer medication during the survival follow-up...
Journal Articles
Shinsuke Uchikawa, Tomokazu Kawaoka, Maiko Namba, Kenichiro Kodama, Kazuki Ohya, Kei Morio, Takashi Nakahara, Eisuke Murakami, Masataka Tsuge, Akira Hiramatsu, Michio Imamura, Shoichi Takahashi, Kazuaki Chayama, Hiroshi Aikata
Journal:
Liver Cancer
Liver Cancer (2020) 9 (2): 148–155.
Published Online: 08 November 2019
... muscle index (SMI) has been reported to be useful for predicting prognosis in hepatocellular carcinoma (HCC). In this study, we analyzed skeletal muscle change during sorafenib and lenvatinib therapy and the association between SMI and prognosis. Methods: A total of 67 patients with advanced HCC...
Journal Articles
Masatoshi Kudo, Kazuomi Ueshima, Yasutaka Chiba, Sadahisa Ogasawara, Shuntaro Obi, Namiki Izumi, Hiroshi Aikata, Hiroaki Nagano, Etsuro Hatano, Yutaka Sasaki, Keisuke Hino, Takashi Kumada, Kazuhide Yamamoto, Yasuharu Imai, Shouta Iwadou, Chikara Ogawa, Takuji Okusaka, Fumihiko Kanai, Yasuaki Arai
Journal:
Liver Cancer
Liver Cancer (2019) 8 (6): 505–519.
Published Online: 08 October 2019
... Objective: In SILIUS (NCT01214343), combination of sorafenib and hepatic arterial infusion chemotherapy did not significantly improve overall survival (OS) in patients with advanced hepatocellular carcinoma (HCC) compared with sorafenib alone. In this study, we explored the relationship between objective...
Journal Articles
Journal:
Liver Cancer
Liver Cancer (2019) 8 (6): 427–446.
Published Online: 29 May 2019
...Lorenza Rimassa; Tiziana Pressiani; Philippe Merle Background: Patients with advanced hepatocellular carcinoma (HCC) typically have poor survival outcomes. Until recently, sorafenib was the only systemic therapy option available and no agents were approved after sorafenib failure. However, rapid...
Journal Articles
Da-Liang Ou, Yu-Yang Lin, Chia-Lang Hsu, Yin-Yao Lin, Chia-Wei Chen, Jhang-Sian Yu, Shi-Chuen Miaw, Ping-Ning Hsu, Ann-Lii Cheng, Chiun Hsu
Journal:
Liver Cancer
Liver Cancer (2019) 8 (3): 155–171.
Published Online: 28 May 2019
.... The difference in treatment response between parental and PD-L1-expressing tumors disappeared when a combination of anti-PD1 and sorafenib was given. Conclusions: PD-L1 expression in HCC cells may inhibit T-cell function in the liver tumor microenvironment. Anti-PD1 therapy appeared more effective in PD-L1...
Journal Articles
Jean-Luc Raoul, Xavier Adhoute, Guillaume Penaranda, Hervé Perrier, Paul Castellani, Valérie Oules, Marc Bourlière
Journal:
Liver Cancer
Liver Cancer (2019) 8 (6): 457–467.
Published Online: 27 March 2019
...Jean-Luc Raoul; Xavier Adhoute; Guillaume Penaranda; Hervé Perrier; Paul Castellani; Valérie Oules; Marc Bourlière Background: Sorafenib is the first-line treatment for advanced hepatocellular carcinoma (HCC). The management of its side effects is improving. This study aimed to assess, in real life...
1